{
    "ticker": "LQR",
    "name": "Liquidia Corporation",
    "description": "Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with serious diseases. Founded in 2004 and headquartered in Durham, North Carolina, Liquidia has pioneered the use of its proprietary PRINT technology, which enables the precise fabrication of nanoparticles for drug delivery. This innovative platform is designed to improve the therapeutic potential of existing drugs and to create new therapies with enhanced efficacy and safety profiles. Liquidia's lead product candidate, LIQ861, is an inhaled formulation of treprostinil, currently in development for the treatment of pulmonary arterial hypertension (PAH). The company aims to address significant unmet medical needs in this space and provide patients with more effective treatment options. Liquidia is committed to advancing the science of drug delivery and improving patient outcomes through its technology and pipeline of products. The company also explores collaborations and partnerships to enhance its research capabilities and expand its product offerings. With a focus on innovation and patient care, Liquidia strives to make a meaningful difference in the lives of patients suffering from serious health conditions.",
    "industry": [
        "Biopharmaceuticals",
        "Drug Delivery"
    ],
    "headquarters": "Durham, North Carolina, USA",
    "founded": "2004",
    "website": "https://www.liquidia.com",
    "ceo": "Nicolas C. D. N. P. H. G. Giordano",
    "social_media": {
        "twitter": "https://twitter.com/LiquidiaCorp",
        "linkedin": "https://www.linkedin.com/company/liquidia-technologies/"
    },
    "investor_relations": "https://investors.liquidia.com",
    "key_executives": [
        {
            "name": "Nicolas C. D. N. P. H. G. Giordano",
            "position": "CEO"
        },
        {
            "name": "Jesse W. C. M. S. H. A. E. E. J. L. Schmid",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "LIQ861"
            ]
        }
    ],
    "seo": {
        "meta_title": "Liquidia Corporation | Innovative Biopharmaceuticals",
        "meta_description": "Explore Liquidia Corporation, a leader in innovative drug delivery solutions for serious diseases. Learn about Liquidia's commitment to patient care and its advanced therapies.",
        "keywords": [
            "Liquidia",
            "Biopharmaceuticals",
            "Drug Delivery",
            "Pulmonary Arterial Hypertension",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What does Liquidia Corporation specialize in?",
            "answer": "Liquidia Corporation specializes in the development of innovative therapies for serious diseases using its proprietary PRINT technology."
        },
        {
            "question": "What is LIQ861?",
            "answer": "LIQ861 is an inhaled formulation of treprostinil developed for the treatment of pulmonary arterial hypertension."
        },
        {
            "question": "Where is Liquidia headquartered?",
            "answer": "Liquidia is headquartered in Durham, North Carolina, USA."
        },
        {
            "question": "When was Liquidia founded?",
            "answer": "Liquidia was founded in 2004."
        }
    ],
    "competitors": [
        "VRTX",
        "AMGN",
        "HGEN",
        "ABT"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "BMY"
    ]
}